Eppendorf with new CEO dual leadership

The Supervisory Board of Eppendorf AG has appointed Eva von Pelt, currently Chief Commercial Officer, and Dr. Peter Fruhstorfer, currently Head of Business Area Sample Handling, as Co-Chief Executive Officers of Eppendorf AG. Both will succeed Thomas Bachmann, the former President & CEO of Eppendorf AG, who has already left the company. Philipp von Loeper, Chairman of the Supervisory Board of Eppendorf AG, states: “On behalf of the entire Supervisory Board, I want to thank Thomas Bachmann for several successful years of leadership. Eppendorf will continue to execute his comprehensive be Eppendorf 2021 strategy and we appreciate his role in developing this transformative initiative for the company.” The goal of be Eppendorf 2021 is to position the company for continues successful development over the long term by specifically addressing the areas of sales, product innovation and a unique corporate culture. The new leadership will continue the be Eppendorf 2021 strategy and drive the implementation with clear priorities and a highly integrative approach. Source: Eppendorf AG from November 6th 2019, www.corporate.eppendorf.com/en/news-media/newsroom/?layer=/en/press-releases/06122019-eppendorf-with-new-ceo-dual-leadership/

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …